News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

The recent update on the palazestrant + ribociclib combination in treating ER+/HER2- metastatic breast cancer shows encouraging results, with a high clinical benefit rate (CBR) across various patient ...

Get detailed information on Ribociclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib, which help slow cancer cell division. Immunotherapy: For some patients with triple-negative breast cancer (which lacks hormone receptors ...

Two other CDK4/6 inhibitors – Novartis' Kisqali (ribociclib) and Eli Lilly's Verzenios (abemaciclib) – have already been approved by NICE for both first- and second-line use in advanced HR+ ...

The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin-dependent kinases driving tumour growth. Immunotherapies like ...

NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

Drugs that act against this target include Ibrance (palbociclib) and Kisqali (ribociclib), both of which are given alongside hormone therapies. A third new target for breast cancer treatment is the ...